Objective: Survival after resections for non-small cell lung cancer remains poor. Recurrent lung cancer remains common. Due to the common risk factor of smoking, cardiovascular deaths occur in the absence of recurrent lung cancer in up to 15% of patients. Aspirin has been proven to reduce cardiovascular mortality as a secondary prophylactic agent, but not as a primary agent. Aspirin being a COX-2 inhibitor has been shown to reduce the chance of metastasis in adenocarcinoma but not squamous carcinoma. We sought to investigate the effect of long-term aspirin therapy on survival post potentially curative surgery. Methods: We analysed a prospective thoracic surgical database, from time period 2003 to date. Patients who were on aspirin pre-operatively, N = 412 were compared to non users, N = 1353. Patient long-term outcome was assessed utilising the national strategic tracking service that operates in the United Kingdom. Cox proportional hazards analysis was used to determine significant factors affecting survival. Results: 100% survival follow up was achieved. Regular users of aspirin had >5% increased survival, which was significant, p = 0.05, despite having a higher cardiovascular risk profile. Mode of death data was not available. Conclusions: Adjuvant aspirin post resection for potentially curative non-small cell lung cancer significantly increases survival. The mechanism of increased survival needs further investigation and is the basis for the trial: Adjuvant Aspirin for Non-Small cell Lung Cancer -The
Introduction
Carcinoma of the lung remains a common cancer with a poor prognosis [1] . Of new cases only 10-15% undergo potentially curative surgical resections. Of these survival is still only about 50% at five years. The peak age incidence of lung cancer is 70-85, with the common risk factor being a history of cigarette smoking (http://info.cancerresearchuk. org/cancerstats).
Cardiovascular deaths peak between the ages of 70 and 85, and have a common risk factor with lung cancer, cigarette smoking [2] . Of patients with lung cancer a significant number die from cardiovascular disease and not from their lung cancer [3] [4] [5] . This forms the basis of actual verses actuarial survival [6] . An agent that reduces the risk of cardiovascular deaths from smoking related cardiovascular disease and reduces the incidence of lung cancer simultaneously would potentially have enormous clinical benefit.
As aspirin is known for its secondary preventive role with regard to cardiovascular disease [7, 8] and is associated with an increased survival benefit in patients with adenocarcinoma [9, 10] .
We hypothesised that aspirin would reduce cardiovascular deaths in all patients post resection for lung cancer and would have an additional beneficial effect with regard to developing recurrent disease in patients who have an adenocarcinoma.
We retrospectively analysed a prospective thoracic surgery database to investigate whether the use of aspirin would be associated with an increased survival post potentially curative lung resection.
Materials and methods
A prospective thoracic surgery database was analysed. Between October 2001 and March 2009, 1816 patients underwent a lung resection for proven or suspected nonsmall cell lung cancer (NSCLC). 51 patients were later found to have stage IV disease or small cell cancer. These were excluded from the analysis. Of the remaining 1765 patients, 412 (23.3%) were recorded as regularly taking aspirin pre-operatively (i.e. with a history of strokes, angina, myocardial infarction or peripheral vascular disease). Survival data for all patients are routinely obtained through the National Strategic Tracing Service. Initially, a Kaplan-Meier survival analysis was undertaken to compare survival in those taking aspirin versus those not taking the drug.
Benchmarking
We benchmarked out long-term outcomes following resection for non-small cell lung cancer, Fig. 1 , against the IASLC Lung Cancer Staging Project 7th edition outcome figures [11, 12] .
Crude analysis
Kaplan-Meier survival curve in Fig. 2a demonstrates the crude survival curve for the aspirin, N = 412, and non-aspirin, N = 1765 groups, for all stages.
Study group characteristics
Possible confounding differences in case-mix between the groups are shown in Table 1 , pre-operative characteristics, and Table 2 , histology and operative characteristics. Differences in categorical variables were evaluated using chi-squared tests, while the Wilcoxon test was used for continuous variables. The influence on survival, of these potentially confounding factors, was investigated further.
Univariate analyses
Univariate analysis of all variables in Table 1 was performed first, with the objective of identifying significant factors for inclusion in a multivariate Cox regression model. Categorical variables were assessed using the Log-Rank Test.
For each of the continuous variables, a univariate Cox regression was performed. Tables 3 and 4 show the results of the univariate analysis.
Histological subtype analysis
Kaplan-Meier sub analysis by adenocarcinoma and squamous carcinoma is shown in Fig. 2b and c, respectively.
Multivariate Cox regression
As confounding variables can cause significant predictors to fail to achieve a p-value <0.05 at the univariate level, univariate predictors were considered potentially important and included in the multivariate model if they were found to have a p-value of less than 0.25. Aspirin use fell just short at 0.26 but, being the variable of interest was also offered to the model.
Following entry into the multivariate Cox regression, a significance level of p <0.05 was considered necessary for variables to remain in the model. Table 5 shows the Cox regression model in its final form.
Using the final Cox regression model shown in Table 5 , the aspirin versus non-aspirin survival curves were risk-adjusted and re-plotted. Therefore, any differences between the curves in Fig. 3 are solely due to the aspirin effect.
Results
100% survival follow up of all patients in our study population was achieved. 
Benchmarking
Benchmarking revealed no significant differences in our long-term outcomes compared to the IASLC Lung Cancer Staging Project 7th edition outcomes.
Crude analysis
The Kaplan-Meier survival curve in Fig. 2a demonstrates the crude survival curve for the aspirin, N = 412, and non aspirin, N = 1765 groups, for all stages. There is no significant difference.
Study group characteristics
It can be seen from Table 1 that the aspirin group having significantly older patients, who were more short of breath, and had a higher incidence of diabetes, hypertension, history of ischaemic heart disease, and peripheral vascular disease.
Data in Table 2 demonstrates that the aspirin group were significantly more likely to undergo a wedge, less likely to undergo a pneumonectomy, and had an earlier stage. There was no significant difference between the incidence of adeno or squamous carcinoma.
Univariate analyses
Univariate analysis, Tables 3 and 4 that revealed, female sex, age at operation, lung function, body mass index above 30, New York Heart Association status, history of chronic obstructive airway disease, having never smoked, excess alcohol consumption, peripheral vascular disease, lobectomy and pneumonectomy, and cancer stage were all significantly associated with survival.
Histological subtype analysis
Kaplan-Meier sub analysis by adenocarcinoma and squamous carcinoma is shown in Fig. 2b and c, respectively demonstrates no significant difference in the outcomes for either subtype of non-small cell lung cancer. Table 5 shows the Cox regression model. In Fig. 3 the Cox adjusted survival estimate of the aspirin effect for all patients, demonstrates that aspirin has a significant survival benefit ( p = 0.05). The mean value of categorical covariates was utilised.
Multivariate Cox regression

Long-term follow up
Our follow up data is up to eight years. Most lung cancer studies only go up to five years. It can be seen that at eight years the aspirin and non-aspirin curves converge. This is due to the natural lifespan of patients, average age 69 in our study and the average life expectancy in the United Kingdom of 77, i.e. eight years.
Discussion
Aspirin may improve survival in patients undergoing potentially curative resections for carcinoma of the lung. This was despite the aspirin group having significantly more cardiovascular risk factors for death than the non uses group. Aspirin thus reduced the mortality in a cohort of patients that would have statistically been expected to have a worse fiveyear outcome.
Whether the data was analysed by stage, histology type or resection type, aspirin resulted in little/no benefit in the first three years postoperatively on outcome. We speculate that death in this period is mainly due to recurrence and aspirin has minimal effect on this. However after three years aspirin seemed to have a significant effect on survival. This beneficial effect seemed to be unaffected by histological type, making our initial hypothesis of adenocarcinomas having a better outcome seem incorrect, implying a beneficial cardiovascular effect for the aspirin.
Basic science research has shown that COX-2 inhibition is associated with a decreased incidence of metastatic disease in adenocarcinoma [13] [14] [15] . Unfortunately sole use of a selective COX-2 inhibitor is associated with an excess of cardiovascular deaths [16] . One of the putative mechanisms of aspirin improving patient survival as a secondary prophylactic agent is via its COX-1 effects on platelet function [7] . Aspirin has unique pharmacological properties due to its irreversible non selective effects of inhibition of COX-1 and COX-2 [17] . Aspirin should be anti metastatic in adenocarcinoma but have little effect with regard to metastasis in squamous carcinoma. The anti platelet effects of aspirin with regard to anti metastatic properties is unknown.
We thus hypothesised that aspirin should reduce recurrent disease in patients with adenocarcinoma and reduce cardiovascular events in all patients. The cardiovascular event rate and mortality can be predicted by utilising the Framingham or POCOCK risk calculator [18] . These calculators estimate that the average 75-year-old smoker who undergoes resection for a potentially curative carcinoma of the lung has between 4 and 8% chance of dying in the next five years from a cardiovascular event. Secondary prevention of cardiovascular evens is proven to occur with the use of non-selective COX inhibition with aspirin. In addition selective COX-2 inhibition is known to increase the cardiovascular mortality rate of patients [16] . Primary prevention of cardiovascular disease with aspirin in unproven, though widely advocated in high risk patients [7] .
We were unable to demonstrate any beneficial effects of aspirin dependent on histology subtype. This has previously been described in prostate cancer [19] , also an adenocarcinoma [9, 10] .
Adjuvant therapy post potentially curative lung resections is still in a state of flux. Treatment of humans with the selective COX-2 inhibitor celecoxib augments the antitumor effects of chemotherapy in patients with non-small cell lung cancer [15, 20] .
In conclusion aspirin use is significantly associated with increased survival post resection for potentially curative carcinoma of the lung.
Limitations
The United Kingdom strategic tracking service does not provide information on mode of death, making elucidation of the mechanism of beneficial effects of aspirin difficult to evaluate. The dose of aspirin was not recorded, although the majority would be on 75 mg/day. About 30% of the population is resistant to the effects of aspirin. The definition of aspirin resistance is difficult to define as no gold standard test exists. We did not test our patients with bed side or formal aggregometry to assess if their platelets were inhibited. In addition we did not analyse platelet count as this data was unavailable.
Future work
A prospective randomised trial of prophylactic aspirin in patients undergoing potentially curative resection for carcinoma of the lung is warranted. (Adjuvant Aspirin for Non-Small cell Lung Cancer -The Big A Trial. www. TheBigATrial.co.uk).
Accepting the suggested hazard ratio of 0.84 and a difference in five-year survival of approximately 6%, various power calculations were performed to derive an estimate of the sample size required for such a trial. Depending on the aspirin:non-aspirin ratio and based on standard assumptions, a combined total of between 2000 and 3000 patients would need to be recruited to detect a significant difference in survival.
